CHYHY News and Press, CHR Hansen Holding A/S ADR

2024-06-28 07:57:06 ET Summary Valuation for Novonesis indicates a "Hold" rating with a price target of 400 DKK/share for double-digit upside potential. Christian Hansen's coverage ends after the merger with Novozymes, resulting in Novonesis. Novonesis is a leading biosolution...

2024-06-19 12:30:00 ET Summary Mar Vista Investment Partners is a registered investment adviser. The Firm offers investment advisory services to individuals, pension and profit-sharing plans, trusts, estates, corporations, as well as other institutional clients. Global markets had...

2024-03-06 01:43:24 ET Summary Novozymes reported its last annual results for fiscal 2023 with revenue growing, but bottom line declining. Novonesis is the new company generated by the merger between Novozymes and Christian Hansen. The stock is trading above intrinsic value on...

2023-12-26 15:52:05 ET Summary Chr. Hansen Holding A/S is a Danish company with above-average growth potential in the enzymes business. The company recorded strong financial performance with 16% organic revenue growth and double-digit growth in core segments. The pending merge...

2023-12-21 10:27:09 ET Summary Novozymes and Chr. Hansen are close to completing their merger, creating a global bio-solutions leader with strong competitive moats. The combined company is expected to deliver higher revenue growth and increased profitability through cost and reven...

2023-10-12 15:05:26 ET Chr. Hansen Holding A/S (CHYHY) Q4 2023 Earnings Conference Call October 12, 2023, 4:00 AM ET Company Participants Mauricio Graber - President and Chief Executive Officer Lise Skaarup Mortensen - Executive Vice President and Chief Financial Off...

2023-10-10 21:54:11 ET Summary Novozymes' stock is declining for almost two years and has lost almost 50% of its previous value. The company reported mediocre half-year results for fiscal 2023. But Novozymes has a wide economic moat around its business, making the company a go...

2023-08-23 21:09:06 ET Summary Christian Hansen is a Danish company with premiumization and low yield, but offers above-average growth potential. Enzymes business, including Christian Hansen, has seen a decline in the past month, presenting a buying opportunity for long-term inves...

2023-07-20 17:05:44 ET Summary Danish bioscience company Chr. Hansen, which specializes in the commercial production of enzymes, has impressive gross margins of over 54% and net margins of over 17%. Despite weak market trends, the company has reported near-double-digit organic rev...

2023-07-06 14:29:43 ET Chr. Hansen Press release ( OTCPK:CHYHY ): Q3 GAAP EPS of Є0.45. Revenue of Є355M (+11.6% Y/Y). For further details see: Chr. Hansen GAAP EPS of Є0.45, revenue of Є355M